NeoGraph Analytics
BiotechnologyNorth America2023 – 2032

Global Europe Precision Medicine Market Size, Share and Trends Analysis

Europe Precision Medicine market valued at USD 24.5B in 2023, projected to reach USD 76.6B by 2032 at 13.5% CAGR.

Revenue, 2023

$24.5B

Forecast, 2032

$76.6B

CAGR, 2024-2032

13.5%

Report Coverage

North America

Code: europe-precision-medicine-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

The European precision medicine market was valued at USD 24.5 billion in 2023 and is projected to reach USD 76.6 billion by 2032, growing at a CAGR of 13.5%. Key growth drivers include rising cancer prevalence, genomic sequencing adoption, and supportive EU regulatory frameworks. Companion diagnostics and next-generation sequencing dominate technology segments, while oncology leads application areas. Germany, France, and the UK are the largest national markets. Strategic collaborations between pharma giants and diagnostics firms are accelerating market expansion.

02

Key Highlights

1

Europe precision medicine market projected at USD 76.6B by 2032, growing 13.5% CAGR from USD 24.5B in 2023.

2

Next-generation sequencing and companion diagnostics lead technology adoption across European hospitals and research labs.

3

Oncology dominates with 40% application share, driven by targeted therapy and immunotherapy biomarker advances.

4

EU regulatory harmonization and Horizon Europe funding accelerate cross-border precision medicine deployment.

03

Market Overview

Market Context

Precision medicine leverages genomic, proteomic, and clinical data to tailor treatments to individual patients. Europe's aging population, rising chronic disease burden, and strong healthcare infrastructure create fertile ground for adoption. The EU's Horizon Europe funding and national genomics strategies further catalyze growth.

Europe's precision medicine market is experiencing high growth driven by genomic advances, rising oncology demand, and EU-funded research initiatives. The region accounts for approximately 30% of the global precision medicine market. Companion diagnostics and NGS platforms are the fastest-growing segments.

Market Stage

High growth

Adoption Level

Growing

Key Trends

AI and machine learning integration in genomic data analysisLiquid biopsy adoption for non-invasive cancer diagnosticsExpansion of national genome sequencing programs across EUGrowing pharma-diagnostic partnerships for companion diagnostics
04

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 13.5%

Base Year (2023)

$24.5B

Forecast (2032)

$76.6B

CAGR (2024-2032)

13.5%

Market size by year, 2024-2032, in USD Billion.
YearMarket size ($ Billion)
2023Base year$24.50B
2024$27.81B
2025$31.56B
2026$35.82B
2027$40.66B
2028$46.15B
2029$52.38B
2030$59.45B
2031$67.47B
2032$76.58B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Forecast Analysis

The 2024-2032 forecast reflects sustained double-digit growth driven by expanding biomarker discovery, liquid biopsy adoption, and AI-powered diagnostics integration. Oncology remains dominant while rare disease and neurology segments show fastest relative growth. Regulatory harmonization across EU states accelerates penetration through 2032.

Regional Market Analysis
Market share and growth rate by region
Regional market analysis — market share, growth rate and largest market by region.
RegionMarket shareGrowth rateLargest market
North America42.0%12.8%United States
Europe30.0%13.5%Germany
Asia Pacific28.0%15.2%China

North America

#1
Share: 42.0%CAGR: 12.8%

Largest market: United States

Europe

#2
Share: 30.0%CAGR: 13.5%

Largest market: Germany

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
05

Market Dynamics

  • Rising cancer incidence and demand for targeted therapies
  • Advances in genomic sequencing and bioinformatics
  • Supportive EU regulatory and funding frameworks
06

Market Segmentation

By Technology
Market share distribution across 4 segments
By Technology — market share by segment, in percent.
SegmentShare
Next-Generation SequencingLargest technology segment driven by declining sequencing costs and clinical adoption across European hospitals.35.0%
Companion DiagnosticsRapidly growing segment supported by regulatory requirements for targeted therapy selection.25.0%
Bioinformatics AnalyticsAI and cloud-based analytics platforms enabling large-scale genomic data interpretation.20.0%
Targeted TherapeuticsPrecision drug development based on genetic profiling of patient populations.20.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
By Application
Market share distribution across 5 segments
By Application — market share by segment, in percent.
SegmentShare
OncologyDominant application area driven by biomarker-guided therapies and liquid biopsy adoption.40.0%
CardiovascularPharmacogenomic testing for anticoagulant and antiplatelet therapy personalization.20.0%
Neurological DisordersGenetic testing for Alzheimer's, Parkinson's, and rare neurological conditions.15.0%
Infectious DiseasesPathogen genomics and host-response profiling for targeted antimicrobial therapy.14.0%
Rare DiseasesWhole-exome and genome sequencing for undiagnosed rare genetic disorders.11.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.

By End User

  • Hospitals and Clinics
  • Research Laboratories
  • Diagnostic Centers
  • Pharmaceutical Companies
07

Regional Analysis

1

North America

Lead: United States
CAGR: 12.8%Share: 42.0%

Largest global market driven by FDA companion diagnostic approvals and major pharma presence.

2

Europe

Lead: Germany
CAGR: 13.5%Share: 30.0%

Second-largest market supported by EU genomics initiatives and strong healthcare infrastructure.

3

Asia Pacific

Lead: China
CAGR: 15.2%Share: 28.0%

Fastest-growing region driven by government genomics programs and expanding healthcare access.

Country-Level Analysis

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Market share and growth rate by country
CountryShareGrowth
United States
38.0%
+12.5%
Germany
12.0%
+14.0%
China
10.0%
+16.5%
08

Competitive Landscape

R

Roche Diagnostics

Switzerland

Leader68B

Dominates precision oncology diagnostics with the NAVIFY platform and extensive companion diagnostics portfolio across European markets.

Global leader in precision oncology diagnostics with the NAVIFY tumor profiling platform and extensive companion diagnostics portfolio.

I

Illumina, Inc.

United States

Challenger4.5B

Leading sequencing technology provider with a strong European install base driving NGS adoption in research and clinical settings.

Dominant NGS technology provider enabling large-scale genomic sequencing for clinical and research applications worldwide.

Q

QIAGEN N.V.

Germany

Follower1.9B

Strong companion diagnostics and molecular sample preparation player with therascreen kits widely used in European laboratories.

Leading molecular diagnostics company specializing in companion diagnostics and sample preparation technologies for precision medicine.

09

Recent Developments

25
2025Roche Diagnostics

Launched next-generation NAVIFY 2.0 platform with expanded biomarker coverage for European oncology centers.

24
2024Illumina, Inc.

Released NovaSeq X Plus sequencer across major European research institutions, reducing per-genome cost below $200.

10

Regulatory Landscape

EU In Vitro Diagnostic Regulation (IVDR 2017/746) governing companion diagnostics market entryEuropean Medicines Agency (EMA) biomarker qualification framework for precision therapy approvals
11

Research Methodology

Primary research

  • Expert interviews with European oncologists and molecular pathologists
  • Surveys of clinical laboratories across 15 EU member states

Secondary research

  • GlobalData industry reports
  • Company financial filings and annual reports
  • EU Horizon Europe program publications

Validation: Triangulation method cross-referencing primary survey data with secondary financial and regulatory sources

12

Strategic Takeaways

Investors

Focus on companion diagnostics and NGS platform companies with strong EU regulatory approvals for highest growth potential.

Operators

Expand biomarker portfolios and forge pharma-diagnostic partnerships to capture growing demand for personalized therapies.

13

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.